Search Results
Division of Cancer Sciences, University of Manchester, Manchester, UK
Search for other papers by Mairéad G McNamara in
Google Scholar
PubMed
Université Paris Sud, Faculté de Médecine de Bicêtre, Le Kremlin-Bicêtre, France
Search for other papers by Jean-Yves Scoazec in
Google Scholar
PubMed
Search for other papers by Thomas Walter in
Google Scholar
PubMed
, 2018 , Rekhtman et al . 2016 ). In the GEP arena, most of the available studies have included not only ‘pure’ NECs, but also mixed neuroendocrine-non neuroendocrine neoplasms. Mixed neuroendocrine non-neuroendocrine neoplasms from the gastro-entero-pancreatic
Search for other papers by Krystallenia I Alexandraki in
Google Scholar
PubMed
Clinic for Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich, Zurich, Switzerland
Search for other papers by Ariadni Spyroglou in
Google Scholar
PubMed
Search for other papers by Stylianos Kykalos in
Google Scholar
PubMed
Endocrine Unit, First Department of Propaedeutic Medicine, Laiko University Hospital, Medical School, National and Kapodistrian University of Athens, Athens, Greece
Search for other papers by Kosmas Daskalakis in
Google Scholar
PubMed
Search for other papers by Georgios Kyriakopoulos in
Google Scholar
PubMed
Search for other papers by Georgios C Sotiropoulos in
Google Scholar
PubMed
Search for other papers by Gregory A Kaltsas in
Google Scholar
PubMed
NET Unit, Royal Free Hospital, London, UK
Barts and the London School of Medicine, London, UK
Search for other papers by Ashley B Grossman in
Google Scholar
PubMed
'Neuroendocrine Tumors/physiology' (Mesh) OR 'Neuroendocrine Tumors/physiopathology' (Mesh) OR 'Gastro-enteropancreatic neuroendocrine tumor' (Supplementary Concept). The databases were searched through until May 2020. We screened 244 articles: all articles were
Search for other papers by Satya Das in
Google Scholar
PubMed
Search for other papers by Liping Du in
Google Scholar
PubMed
Search for other papers by Aimee Schad in
Google Scholar
PubMed
Search for other papers by Shikha Jain in
Google Scholar
PubMed
Search for other papers by Aaron Jessop in
Google Scholar
PubMed
Search for other papers by Chirayu Shah in
Google Scholar
PubMed
Search for other papers by David Eisner in
Google Scholar
PubMed
Search for other papers by Dana Cardin in
Google Scholar
PubMed
Search for other papers by Kristen Ciombor in
Google Scholar
PubMed
Search for other papers by Laura Goff in
Google Scholar
PubMed
Search for other papers by Marques Bradshaw in
Google Scholar
PubMed
Search for other papers by Dominique Delbeke in
Google Scholar
PubMed
Search for other papers by Martin Sandler in
Google Scholar
PubMed
Search for other papers by Jordan Berlin in
Google Scholar
PubMed
) in 2018 for patients with gastroenteropancreatic NETs with somatostatin receptor positive disease based on the NETTER-1 study and several large cohort studies from Europe ( Brabander et al. 2017 , Strosberg et al. 2017 ). Although neither EMA nor
Maimonides Institute for Biomedical Research of Cordoba (IMIBIC); Reina Sofia University Hospital, Córdoba, Spain
Search for other papers by Aura D Herrera-Martínez in
Google Scholar
PubMed
Search for other papers by Leo J Hofland in
Google Scholar
PubMed
Search for other papers by María A Gálvez Moreno in
Google Scholar
PubMed
Search for other papers by Justo P Castaño in
Google Scholar
PubMed
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Richard A Feelders in
Google Scholar
PubMed
also referred to as gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) ( Modlin et al . 2008 , Xavier et al . 2016 ). The annual NENs incidence increases over time, although it is not known whether this is a true increase in NEN incidence
Search for other papers by Tessa Brabander in
Google Scholar
PubMed
Department of Molecular Genetics, Erasmus Medical Center, Rotterdam, The Netherlands
Search for other papers by Julie Nonnekens in
Google Scholar
PubMed
Search for other papers by Johannes Hofland in
Google Scholar
PubMed
Background Well-differentiated neuroendocrine neoplasms (NENs) of the gastroenteropancreatic system are characterised by a low mutational burden and indolent tumour growth. These features contribute to the poor success rates of cytotoxic
Search for other papers by Wouter W de Herder in
Google Scholar
PubMed
Search for other papers by Erik P Krenning in
Google Scholar
PubMed
Search for other papers by Gabriel P Krestin in
Google Scholar
PubMed
R de Jong M de Herder WW Krenning EP 2010 Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocrine-Related Cancer 17 R53 – R73 . ( doi:10.1677/ERC-09-0078 ) Teunissen JJ
Search for other papers by Maria Chiara Zatelli in
Google Scholar
PubMed
Search for other papers by Giuseppe Fanciulli in
Google Scholar
PubMed
Search for other papers by Pasqualino Malandrino in
Google Scholar
PubMed
Search for other papers by Valeria Ramundo in
Google Scholar
PubMed
Search for other papers by Antongiulio Faggiano in
Google Scholar
PubMed
Search for other papers by Annamaria Colao in
Google Scholar
PubMed
Search for other papers by on behalf of NIKE Group in
Google Scholar
PubMed
. (2015) identified KRAS mutations in 13 colorectal and two in gastric neuroendocrine carcinomas (NEC) among 53 cases of gastro-entero-pancreatic NEC. KRAS somatic oncogenic mutations characterize cancer patients who do not benefit from everolimus
Department of Oncology, Ryhov County Hospital, Jönköping, Sweden
Search for other papers by Dimitrios Papantoniou in
Google Scholar
PubMed
Search for other papers by Malin Grönberg in
Google Scholar
PubMed
Search for other papers by Espen Thiis-Evensen in
Google Scholar
PubMed
University of Bergen, Deptartment of Clinical Medicine, Bergen, Norway
Search for other papers by Halfdan Sorbye in
Google Scholar
PubMed
Department of Surgery, Ryhov County Hospital, Jönköping, Sweden
Search for other papers by Kalle Landerholm in
Google Scholar
PubMed
Search for other papers by Staffan Welin in
Google Scholar
PubMed
Search for other papers by Eva Tiensuu Janson in
Google Scholar
PubMed
C Schade-Brittinger C Barth P Moll R 2005 Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial . Clinical Gastroenterology and Hepatology 3 761 – 771 . ( https://doi.org/10.1016/S
Search for other papers by Matthew H Kulke in
Google Scholar
PubMed
IFN-α, is controversial ( Saltz et al. 1993 ). Radiologic evidence of tumor regression following treatment with these agents is rare. In a small study involving 21 patients with metastatic gastroenteropancreatic neuroendocrine tumors, a combined
Search for other papers by Mojun Zhu in
Google Scholar
PubMed
Search for other papers by Karl R Sorenson in
Google Scholar
PubMed
Search for other papers by Rebecca Liu in
Google Scholar
PubMed
Search for other papers by Bonnie E Gould Rothberg in
Google Scholar
PubMed
Search for other papers by Thorvardur R Halfdanarson in
Google Scholar
PubMed
the following three queries: (pancreas OR pancreatic OR gastroenteropancreatic) AND (neuroendocrine OR endocrine) AND (prognos* OR surviv* OR predict*) AND (immunost* OR immunohistoch*) (pancreas) OR pancreatic OR gastroenteropancreatic